Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Northern Trust Corp reduced its stake in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) by 6.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 66,682 shares of the company’s stock after selling 4,358 shares during the quarter. Northern Trust Corp owned approximately 0.21% of Anixa Biosciences worth $155,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares during the period. LPL Financial LLC grew its position in shares of Anixa Biosciences by 37.2% in the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after buying an additional 11,633 shares during the period. Finally, Prosperity Wealth Management Inc. purchased a new stake in shares of Anixa Biosciences in the 4th quarter worth about $54,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ANIX has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, March 25th. Maxim Group initiated coverage on shares of Anixa Biosciences in a research report on Friday, March 21st. They issued a “buy” rating and a $10.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Thursday, May 29th.

Anixa Biosciences Price Performance

NASDAQ:ANIX opened at $2.82 on Wednesday. The firm’s 50-day moving average price is $2.67 and its 200-day moving average price is $2.80. The company has a market capitalization of $90.80 million, a PE ratio of -7.23 and a beta of 0.43. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $4.20.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Equities analysts anticipate that Anixa Biosciences, Inc. will post -0.41 EPS for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.